A Heart Transplant Recipient Lost Due to Pneumocystis jiroveci Pneumonia Under Trimethoprim-Sulfamethoxazole Prophylaxis: Case Report

Basit Öğe Kaydı
dc.authoridKayabas, Uner/0000-0002-5323-0796
dc.authoridGulbas, Gazi/0000-0002-9435-8307
dc.authoridBayindir, Yasar/0000-0003-3930-774X
dc.authoridGedik, Ender/0000-0002-7175-207X
dc.authorwosidKayabas, Uner/JRX-1616-2023
dc.authorwosidGulbas, Gazi/ABI-5182-2020
dc.authorwosidBayindir, Yasar/T-1523-2017
dc.authorwosidGedik, Ender/ABI-2971-2020
dc.contributor.authorCelik, Tuncay
dc.contributor.authorGedik, Ender
dc.contributor.authorKayabas, Uner
dc.contributor.authorBayindir, Yasar
dc.contributor.authorGulbas, Gazi
dc.contributor.authorFirat, Ahmet Kemal
dc.contributor.authorTogal, Turkan
dc.date.accessioned2024-08-04T20:32:40Z
dc.date.available2024-08-04T20:32:40Z
dc.date.issued2010
dc.departmentİnönü Üniversitesien_US
dc.description.abstractInfections in solid-organ transplant recipients are the most important causes of morbidity and mortality. A primary goal in organ transplant is the prevention or effective treatment of infection, which is the most-common life-threatening complication of long-term immunosuppressive therapy. A 21-year-old woman who underwent heart transplant 3 years previous owing to dilated cardiomyopathy was referred to our hospital with symptoms of high fever and cough. The patient's history revealed that she had received a trimethoprim-sulfamethoxazole double-strength tablet each day for prophylactic purposes. On chest radiograph, pneumonia was detected, and in broncho-alveolar lavage sample, Pneumocystis jiroveci cysts were found. After diagnosing P. jiroveci pneumonia, trimethoprim-sulfamethoxazole was initiated at 20 mg/kg/d including intravenous trimethoprim in divided dosages every 6 hours. On the sixth day of therapy, she died in intensive care unit. In solid-organ transplant recipients, although antipneumocystis prophylaxis is recommended within the first 6 to 12 months after transplant, lifelong prophylaxis is also used in several settings. In addition, the physician should keep in mind that P. jiroveci pneumonia may develop in solid organ recipients, despite trimethoprim-sulfamethoxazole prophylaxis.en_US
dc.identifier.endpage328en_US
dc.identifier.issn1304-0855
dc.identifier.issue4en_US
dc.identifier.pmid21143101en_US
dc.identifier.scopus2-s2.0-78650552849en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage325en_US
dc.identifier.urihttps://hdl.handle.net/11616/95221
dc.identifier.volume8en_US
dc.identifier.wosWOS:000287260900011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBaskent Univen_US
dc.relation.ispartofExperimental and Clinical Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSolid organ transplanten_US
dc.subjectPneumocystosisen_US
dc.subjectChemoprophylaxisen_US
dc.titleA Heart Transplant Recipient Lost Due to Pneumocystis jiroveci Pneumonia Under Trimethoprim-Sulfamethoxazole Prophylaxis: Case Reporten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu